Video - Results from #30

CANCER-GG1 VL

Prostate Cancer Markers: Challenges in Differentiating Low-Risk Cases "Discussion" Details At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, experts debate the effectiveness of biomarkers in distinguishing between different grades of prostate cancer, particularly in active surveillance cohorts. The conversation highlights the difficulty in identifying the small percentage of high-risk patients within low-risk cohorts. The discussion c...
Genomics in Prostate Cancer: Limitations in Active Surveillance "Presentation" - Felix Feng Details At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Felix Feng discusses the limitations of genomics and AI in resolving the prostate cancer nomenclature question. He emphasizes that current genomic tools have not proven effective in active surveillance contexts, citing studies showing limited prognostic value beyond clinical variables. Dr. Feng e...
Redefining Prostate Cancer: The Debate on Grade Group 1 Classification "Discussion" Details At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, experts explore the complexities of prostate cancer diagnosis and classification. The participants debate the use of terms like "cancer" and "carcinoma," and discuss the potential for reclassifying some Grade Group 1 cancers. They explore the historical and biological basis for using basal cell l...
Reclassifying Prostate Cancer: Clinical Implications of Grade Group 1 Nomenclature Change "Discussion" Details At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, experts explore the potential clinical implications of reclassifying low-grade prostate cancer. The group anticipates decreased treatment rates for Grade Group 1 disease, reduced patient burden, and less intensive surveillance. They also consider risks such as increased loss to follow-up. The con...
Prostate Cancer Nomenclature Change: Impact on Advocacy and Patient Care "Discussion" Details At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, experts discuss the potential impacts of changing the nomenclature for low-grade prostate cancer. The group concludes that advocacy organizations are unlikely to be threatened by the change, as it may improve quality of life without affecting survival. They raise concerns about certain population...
Prostate Cancer Nomenclature Change: Societal and Clinical Implications "Discussion" Details At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, experts discuss the potential non-clinical implications of changing prostate cancer nomenclature. The group identifies positive outcomes such as reduced patient anxiety and costs, and potentially improved insurance access. Negative consequences could include decreased philanthropy and grant fundi...
Prostate Cancer Management: Rethinking Active Surveillance and Nomenclature "Discussion" Details At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, experts explore several aspects of prostate cancer diagnosis and active surveillance. The group raises questions about the financial toxicity of active surveillance, particularly for underserved populations. They also consider whether high-quality access to care could improve surveillance outcome...
Exploring Financial Toxicity and Cultural Differences in Prostate Cancer Active Surveillance "Discussion" Details At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, experts discuss several key issues in prostate cancer management and nomenclature. The group raises questions about the financial toxicity of active surveillance, particularly for underserved populations, and whether high-quality access to care could improve surveillance outcomes. They also consi...

CANCER-GG1 VL

Login